Ignite Creation Date:
2025-12-24 @ 6:42 PM
Ignite Modification Date:
2025-12-25 @ 4:12 PM
Study NCT ID:
NCT00540657
Status:
COMPLETED
Last Update Posted:
2025-03-06
First Post:
2007-10-05
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Study of CCX282-B in Patients With Celiac Disease
Sponsor:
Amgen
Organization:
Study Overview
Official Title:
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease
Status:
COMPLETED
Status Verified Date:
2025-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease
Detailed Description:
Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: